Gene: BCR

613
ALL|BCR1|CML|D22S11|D22S662|PHL
BCR, RhoGEF and GTPase activating protein
protein-coding
22q11.23
Ensembl:ENSG00000186716 MIM:151410 Vega:OTTHUMG00000150655 UniprotKB:P11274
NG_009244.1
PubMed
0   ANCO-SNPs
ND
6   
6.582e-1 (AD)  6.601e-1 (ND)   (Frontal_Cortex)
8.623e-2 (AD)  7.327e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CDH40.84
ABAT0.833
TFE30.829
SLC25A230.829
MAPKAP10.827
DCAF110.827
SCMH10.825
SGSM20.825
DCLK20.824
AMPD20.824

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.689
OR4F29-0.63
CTNNA3-0.384
TRPV5-0.341
VRK2-0.34
SGMS2-0.334
CLEC6A-0.328
CNTF-0.324
KCNJ15-0.322
TMEM139-0.308

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB01254DasatinibSmall Molecule302962-49-8Approved|InvestigationalTarget
DB06616BosutinibSmall Molecule380843-75-4ApprovedTarget
DB08901PonatinibSmall Molecule943319-70-8Approved|InvestigationalTarget
ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of BCR mRNA"27291303
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]16849647
C4988264-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
C4988264-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]16849647
C4988264-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of BCR protein mutant form19878872
D000255Adenosine Triphosphate[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein19366808
D000255Adenosine Triphosphatesorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]19366808
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of BCR gene28458013
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of BCR mRNA24449571
C058317arsenic disulfidearsenic disulfide results in decreased expression of and results in decreased activity of BCR protein mutant form12421474
C006632arsenic trioxidearsenic trioxide promotes the reaction [CTSB protein results in increased degradation of BCR protein mutant form]22898604
C006632arsenic trioxidearsenic trioxide promotes the reaction [SQSTM1 protein results in increased localization of BCR protein mutant form]22898604
C006632arsenic trioxidearsenic trioxide results in decreased expression of BCR mRNA20458559
C006632arsenic trioxidearsenic trioxide results in decreased expression of BCR protein mutant form14633726|2233006
C006632arsenic trioxidearsenic trioxide results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]24129092
C006632arsenic trioxidearsenic trioxide results in increased degradation of BCR protein mutant form22898604
C006632arsenic trioxidearsenic trioxide results in increased expression of BCR mRNA22521957
C006632arsenic trioxideATG7 protein promotes the reaction [arsenic trioxide results in increased degradation of BCR protein mutant form]22898604
C006632arsenic trioxideBECN1 protein promotes the reaction [arsenic trioxide results in increased degradation of BCR protein mutant form]22898604
C006632arsenic trioxideSQSTM1 protein promotes the reaction [arsenic trioxide results in increased degradation of BCR protein mutant form]22898604
D001280AtrazineAtrazine results in decreased expression of BCR mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of BCR mRNA26238291
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of BCR mRNA19770486
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of BCR mRNA"26238291
D004958EstradiolEstradiol affects the expression of BCR mRNA22574217
D004958EstradiolEstradiol results in increased expression of BCR mRNA23019147
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in decreased expression of BCR mRNA25270620
C006780bisphenol Abisphenol A results in increased expression of BCR mRNA25181051
D000069286BortezomibBortezomib results in decreased expression of BCR mRNA20977926
D004390ChlorpyrifosChlorpyrifos results in increased expression of BCR protein16790487
D004390ChlorpyrifosChlorpyrifos results in decreased expression of BCR mRNA18668222
C018021cobaltous chloridecobaltous chloride results in decreased expression of BCR mRNA19320972
D019327Copper SulfateCopper Sulfate results in decreased expression of BCR mRNA19549813
C052570cyfluthrincyfluthrin results in increased expression of BCR protein16790487
D000069439DasatinibDasatinib binds to BCR protein mutant form17684099|1818038
D000069439Dasatinib[Dasatinib co-treated with vorinostat] results in decreased expression of BCR protein mutant form17020995
D000069439Dasatinib[Dasatinib co-treated with vorinostat] results in decreased phosphorylation of BCR protein mutant form17020995
D000069439DasatinibDasatinib inhibits the reaction [BCR protein mutant form results in increased phosphorylation of CRKL protein]19100678
D000069439DasatinibDasatinib results in decreased activity of BCR protein mutant form19100678
D000069439DasatinibDasatinib results in decreased phosphorylation of BCR protein mutant form17020995|1987887
D000069439DasatinibDasatinib results in decreased activity of BCR protein mutant form20222756
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of BCR mRNA]27941970
D003907DexamethasoneDexamethasone results in decreased expression of BCR mRNA20032058
D003907DexamethasoneTestosterone inhibits the reaction [Dexamethasone results in decreased expression of BCR mRNA]20032058
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of BCR mRNA21266533
C000944dicrotophosdicrotophos results in increased expression of BCR mRNA28302478
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of BCR mRNA26924002
D004041Dietary FatsDietary Fats results in decreased expression of BCR mRNA25016146
D004052Diethylnitrosamine[Fenofibrate co-treated with Diethylnitrosamine] results in increased expression of BCR mRNA18253720
D011345Fenofibrate[Fenofibrate co-treated with Diethylnitrosamine] results in increased expression of BCR mRNA18253720
D005419FlavonoidsFlavonoids results in decreased expression of BCR mRNA15465739
D005707Gallic AcidGallic Acid promotes the reaction [Imatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]]22245431
D005707Gallic AcidGallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]22245431
D005707Gallic AcidImatinib Mesylate promotes the reaction [Gallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]]22245431
D006632Histamine2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
D006632Histamine4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
D006632Histamine[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine16849647
D006632HistamineImatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
D000068877Imatinib MesylateGallic Acid promotes the reaction [Imatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]]22245431
D000068877Imatinib MesylateImatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]16849647
D000068877Imatinib MesylateImatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]16849647
D000068877Imatinib MesylateImatinib Mesylate promotes the reaction [Gallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]]22245431
D000068877Imatinib MesylateImatinib Mesylate results in decreased activity of BCR protein mutant form15329907|1560422
D000068877Imatinib MesylateImatinib Mesylate results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]22397755
D000068877Imatinib MesylateImatinib Mesylate results in decreased phosphorylation of BCR protein mutant form19366808|1987887
D000068877Imatinib MesylateImatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]22245431
D000068877Imatinib Mesylate[vorinostat co-treated with Imatinib Mesylate] results in decreased expression of BCR protein mutant form12446442
D000068877Imatinib Mesylate[vorinostat co-treated with Imatinib Mesylate] results in decreased phosphorylation of BCR protein mutant form12446442
D000068877Imatinib MesylateImatinib Mesylate results in decreased activity of BCR protein mutant form20222756
C051890irinotecanirinotecan analog results in decreased expression of BCR mRNA18927307
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of BCR mRNA26011545
C517284monomethyl phthalatemonomethyl phthalate affects the expression of BCR mRNA26924002
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of BCR mRNA19812364
C498045NCX 4040NCX 4040 results in increased expression of BCR mRNA20188076
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of BCR mRNA18593933
D010634PhenobarbitalPhenobarbital results in decreased expression of BCR mRNA25270620
D010936Plant ExtractsPlant Extracts results in decreased expression of BCR mRNA15465739
D059808PolyphenolsPolyphenols results in decreased expression of BCR mRNA15465739
C545373ponatinibponatinib results in decreased phosphorylation of BCR protein mutant form19878872
C470893purmorphaminepurmorphamine inhibits the reaction [resveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]]22397755
D011794QuercetinQuercetin results in decreased expression of BCR mRNA14715546
C059514resveratrolpurmorphamine inhibits the reaction [resveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]]22397755
C059514resveratrolresveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]22397755
D017632Asbestos, Serpentine"Asbestos, Serpentine results in increased expression of BCR mRNA"21148743
C471405sorafenibsorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]19366808
C471405sorafenibsorafenib results in decreased activity of BCR protein mutant form19366808
C471405sorafenibsorafenib results in decreased phosphorylation of BCR protein mutant form19366808
D013739TestosteroneTestosterone inhibits the reaction [Dexamethasone results in decreased expression of BCR mRNA]20032058
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of BCR mRNA11007951
D013806TheophyllineTheophylline results in increased expression of BCR mRNA16083514
C012589trichostatin Atrichostatin A results in decreased expression of BCR mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of BCR mRNA"26179874
D014635Valproic AcidValproic Acid results in increased expression of BCR mRNA23179753|2718838
C025643vinclozolinvinclozolin affects the expression of BCR mRNA19015723
C025643vinclozolinvinclozolin results in decreased expression of BCR mRNA23034163
C111237vorinostat[Dasatinib co-treated with vorinostat] results in decreased expression of BCR protein mutant form17020995
C111237vorinostat[Dasatinib co-treated with vorinostat] results in decreased phosphorylation of BCR protein mutant form17020995
C111237vorinostat[vorinostat co-treated with Imatinib Mesylate] results in decreased expression of BCR protein mutant form12446442
C111237vorinostat[vorinostat co-treated with Imatinib Mesylate] results in decreased phosphorylation of BCR protein mutant form12446442
C111237vorinostatvorinostat results in decreased expression of BCR mRNA mutant form12446442
C111237vorinostatvorinostat results in decreased expression of BCR protein mutant form12446442
C111237vorinostat[VX680 co-treated with vorinostat] results in decreased activity of BCR protein mutant form18829489
C484810VX680[VX680 co-treated with vorinostat] results in decreased activity of BCR protein mutant form18829489
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of BCR mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004674protein serine/threonine kinase activity-IEA-  
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0005089Rho guanyl-nucleotide exchange factor activity-IEA-  
GO:0005096GTPase activator activity-TAS-  
GO:0005515protein binding-IPI8112292  8955135  8995379  9174058  9178913  10887132  
11726515  15494376  16169070  21706016  22153077  25241761  
25331951  
GO:0005524ATP binding-IEA-  
GO:0016301kinase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0002692negative regulation of cellular extravasation-IEA-  
GO:0003014renal system process-IEA-  
GO:0006468protein phosphorylation-TAS1657398  
GO:0007165signal transduction-TAS1657398  
GO:0007420brain development-IEA-  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0030036actin cytoskeleton organization-IEA-  
GO:0035023regulation of Rho protein signal transduction-IEA-  
GO:0035556intracellular signal transduction-IEA-  
GO:0042472inner ear morphogenesis-IEA-  
GO:0043114regulation of vascular permeability-IEA-  
GO:0043314negative regulation of neutrophil degranulation-IEA-  
GO:0046777protein autophosphorylation-IEA-  
GO:0048008platelet-derived growth factor receptor signaling pathway-IEA-  
GO:0048872homeostasis of number of cells-IEA-  
GO:0050728negative regulation of inflammatory response-IEA-  
GO:0050766positive regulation of phagocytosis-IEA-  
GO:0050885neuromuscular process controlling balance-IEA-  
GO:0051056regulation of small GTPase mediated signal transduction-TAS-  
GO:0051171regulation of nitrogen compound metabolic process-IEA-  
GO:0051726regulation of cell cycle-IEA-  
GO:0060216definitive hemopoiesis-IEA-  
GO:0060268negative regulation of respiratory burst-IEA-  
GO:0060313negative regulation of blood vessel remodeling-IEA-  
GO:0065002intracellular protein transmembrane transport-IEA-  
GO:0071222cellular response to lipopolysaccharide-IEA-  
GO:2000378negative regulation of reactive oxygen species metabolic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0014069postsynaptic density-ISS-  
GO:0016020membrane-HDA19946888  
GO:0016020membrane-IBA21873635  
GO:0030054cell junction-IEA-  
GO:0032991protein-containing complex-IDA23382219  
GO:0045211postsynaptic membrane-IEA-  
GO:0070062extracellular exosome-HDA19056867  
KEGG ID KEGG Term
hsa05200Pathways in cancer
hsa05220Chronic myeloid leukemia
Reactome ID Reactome Term Evidence
R-HSA-1226099Signaling by FGFR in diseaseTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1643685DiseaseTAS
R-HSA-1839117Signaling by cytosolic FGFR1 fusion mutantsTAS
R-HSA-1839124FGFR1 mutant receptor activationTAS
R-HSA-194315Signaling by Rho GTPasesTAS
R-HSA-194840Rho GTPase cycleTAS
R-HSA-5655302Signaling by FGFR1 in diseaseTAS
R-HSA-5663202Diseases of signal transductionTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24142566When water does not clear the smut from the smoke. (2013 Oct 18)Bonadies NBMJ Case Rep
25807961Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. (2016 Jan)Schwarz JEur J Haematol
28184442Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. (2017 May 1)Sato NJpn J Clin Oncol
17196995aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL. (2007 Feb 3)Bartos JDMutat Res
18586919Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? (2008 Jun)Lichtman MAOncologist
22056474Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. (2013 Jun 5)Banegas JRInt J Cardiol